AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBD
Description: DBD:one dose of medicine twice per day, orally
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin:90mg/m2, d1, q3w\*4
Study NCT00628537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BION stimulation
Description: BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises.
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT02444923 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)
Description: Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
Study NCT02444923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)
Description: Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
Study NCT02444923 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)
Description: The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
Study NCT02444923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)
Description: The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
Study NCT03463382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane block will be administered under general anesthesia before the surgery
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: Epirubicin:90mg/m2, d1, q3w\*4
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel:75mg/m2, d1, q3w\*4
Study NCT02005783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel:75mg/m2, d1, q3w\*4
Study NCT04010162 — intervention group
Intervention type: OTHER
Intervention: Mesh debate awareness survey
Description: A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute
Study NCT03447821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Rifamycin SV dosage
Study NCT03447821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 mg Rifamycin SV dosage
Study NCT03447821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200 mg Rifamycin SV dosage
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Urography
Description: Undergo a CT urography
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT Urography
Description: Undergo a CT urography
Study NCT03463382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block will be administered under general anesthesia before the surgery
Study NCT03463382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: 0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
Study NCT02791360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Study NCT02360371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medication
Description: Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
Study NCT02360371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Within-subject test of blinded study medication
Description: Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
Study NCT04685538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 3%
Description: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.
Study NCT04685538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine 0.5%
Description: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.
Study NCT03142087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercise
Study NCT03040102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospice Video Educational Tool
Description: it's a 6 minute video regarding hospice care
Study NCT03040102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care practice is used
Study NCT01731990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab (ACZ885)
Description: Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
Study NCT01731990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of Canakinumab
Study NCT04051112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: 10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
Study NCT01784978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg pd
Study NCT01784978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg pd
Study NCT04748523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
Study NCT04748523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
Study NCT02920450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg
Study NCT03256331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEL-X-HG
Description: This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2.
Study NCT03330821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03330821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT03330821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03330821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT03330821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01293539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan hydrochloride
Description: Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle.
Study NCT04457336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study NCT04457336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study NCT03286010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women@Heart Program
Description: The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
Study NCT05302830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snackability app
Description: This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
Study NCT05302830 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
Study NCT02920450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
Study NCT02920450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
Study NCT01921452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative POC TSH Kit
Description: A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
Study NCT04885153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
Study NCT04885153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
Study NCT02992418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
Study NCT02992418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
Description: 0.5 mL, intramuscularly (IM) at Month 1.
Study NCT03169868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sano Patient Medication Profile
Description: The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
Study NCT03200431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed strip.
Study NCT00588237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel,Cisplatin, Bevacizumab
Description: IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
Study NCT02792309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MotherWise Program
Description: Healthy Marriage or Relationship Education services for pregnant women.
Study NCT02096952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release liquid formulation
Study NCT03275246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-PSI Knee System
Description: Patients are operated with X-PSI Knee System guides
Study NCT03999099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Description: Suvorexant at a high dose (20 mg)
Study NCT03999099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Description: Suvorexant at a low dose (10 mg)
Study NCT03999099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
Study NCT00635349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
Study NCT01784978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg pd
Study NCT01784978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10 mg pd
Study NCT00009698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SQ and IV
Study NCT01506713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg
Study NCT01506713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg
Study NCT01165437 — intervention group
Intervention type: DEVICE
Intervention: Blood Pressure Measurement
Description: Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
Study NCT03644212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
Study NCT00590720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 50 mg
Description: MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
Study NCT00590720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo administered as a subcutaneous injection twice weekly for 4 weeks
Study NCT00224042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate complex in sucrose
Description: Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
Study NCT00224042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate 325 mg three times daily for 6 weeks
Study NCT04717791 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vivaer® ARC Stylus
Description: The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
Study NCT00766311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gross Motor Function
Description: The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.